Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Angelalign IPO Valuation: Limited Upside from the Top End

Full Truck Alliance IPO: In Early Stage of Monetisation

JD Logistics IPO: Thoughts on First Day Trading

JW Therapeutics: Limited Upside from the Top End; Further Potential if Other Drugs Become Successful

Zhaoke Opthalmology IPO: Promising Drug Candidates; but Commercialisation May Take Longer

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

JD Logistics IPO Valuation: Implied Offer Multiples Are Not Cheap but Justifiable

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

CARSgen Therapeutics / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/carsgen-therapeutics-ltd" target="_blank" data-smartkarma-citation="entities:32213:1" rel="noopener">CARSgen Therapeutics (1186504D CH)</a>  is a biopharmaceutical company in China and the US developing CAR-T cell therapies for treating solid tumours and haematological malignancies. The company has a pipeline of 11 products of which six are at clinical stage. The company has filed for an IPO to list its shares on the Hong Kong Stock Exchange and plans to raise proceeds of US$400-500m.</p><p>Given that the company currently does not have any products approved for commercial sale, it does not generate any revenues from product sales. However, the company’s drug development pipeline includes a few drug candidates that have limited competition and strong performance potential.</p>

CARSgen Therapeutics (1186504D CH)  is a biopharmaceutical company in China and the US developing CAR-T cell therapies for treating solid tumours and haematological malignancies. The company has a pipeline of 11 products of which six are at clinical stage. The company has filed for an IPO to list its shares on the Hong Kong Stock Exchange and plans to raise proceeds of US$400-500m.Given that the company currently does not have any products approved for commercial sale, it does not generate any revenues from product sales. However, the company’s drug development pipeline includes a few drug candidates that have limited competition and strong performance potential.

CARSgen Therapeutics IPO: Catalyzing Cancer Therapies